GV 196771A: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 21202952 |
| MeSH ID | M0306632 |
| Synonym |
|---|
| gv 196771a |
| 4,6-dichloro-3-{[(3e)-2-oxo-1-phenylpyrrolidin-3-ylidene]methyl}-1h-indole-2-carboxylate |
| gtpl4208 |
| gv196771a |
| Q27077934 |
| 4,6-dichloro-3-[(e)-(2-oxo-1-phenylpyrrolidin-3-ylidene)methyl]-1h-indole-2-carboxylate |
| Excerpt | Reference | Relevance |
|---|---|---|
| " GV196771 has low oral bioavailability (<10%) and plasma clearance ( approximately 2 ml/min/kg) in rats." | ( The systemic exposure of an N-methyl-D-aspartate receptor antagonist is limited in mice by the P-glycoprotein and breast cancer resistance protein efflux transporters. Barnaby, RJ; Baughman, TM; Bertolotti, L; Humphreys, JE; Jordan, KH; Mote, AL; Polli, JW; Read, KD; Serabjit-Singh, CJ; Vitulli, G; Webster, LO, 2004) | 0.32 |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1346641 | Rat GluN1 (Ionotropic glutamate receptors) | 2000 | British journal of pharmacology, May, Volume: 130, Issue:1 | Characterization of the binding of two novel glycine site antagonists to cloned NMDA receptors: evidence for two pharmacological classes of antagonists. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (25.00) | 18.2507 |
| 2000's | 6 (75.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.96) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 2 (25.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (75.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||